Roche’s PD-L1 play­er Tecen­triq fails PhI­II for ovar­i­an can­cer

Roche’s hit-and-miss record on Tecen­triq has post­ed an­oth­er miss.

The phar­ma gi­ant re­port­ed this morn­ing that the PD-L1 check­point failed a Phase III tri­al for women with ad­vanced, front line ovar­i­an can­cer, one of sev­er­al hard-to-hit can­cers that’s de­fied a va­ri­ety of ap­proach­es. Much of the new R&D in ovar­i­an can­cer re­mains fo­cused on PARP, where As­traZeneca’s Lyn­parza holds sway.

In this tri­al Roche com­bined their PD-L1 Tecen­triq with Avastin. But it’s been one of dozens of Phase III tri­als in the works for the check­point crew, as more com­pa­nies an­gle to jump in­to the mar­ket be­hind the two lead­ers — Mer­ck’s Keytru­da and Bris­tol-My­ers Squibb’s Op­di­vo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER